Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy

References

• Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer , Lyons, France. Int J Cancer 1977; 20: 680–688.
   Google Scholar
• Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906–913.
   PubMed Web of Science ®Google Scholar
• Ma RW, Chapman KJ. A systematic review of the effect of diet in prostate cancer prevention and treatment. Hum Nutr Diet 2009; 22: 187–199.
   PubMed Web of Science ®Google Scholar
• Drasch G, Schöpfer J, Schrauzer GN. Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 2005; 103: 103–107.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Wer Z. Inflammation and cancer. Nature 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176: 1012–1016.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu Rev Pathol 2006;1:243–271.
   PubMed Web of Science ®Google Scholar
• Zenzmaier C, Untergasser G, Berger P. Aging of the prostate epithelial stem/progenitor cell. Exp Gerontol 2008; 43: 981–985.
   PubMedGoogle Scholar
• Barry MJ. Prostate-specific–antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344: 1373–1377.
   PubMed Web of Science ®Google Scholar
• Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res 2007; 175: 65–81.
   PubMedGoogle Scholar
• Wilson SS, Crawford ED. Screening for prostate cancer: current recommendations. Urol Clin North Am 2004; 31: 219–26.
   PubMedGoogle Scholar
• Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. J Urol 2009; 182: 499–507.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–1328.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20Suppl 3: S19–S26.
   Google Scholar
• Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia Arch Ital Urol Androl 2009; 81: 1–8.
   PubMedGoogle Scholar
• Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl. Cancer Inst 2006; 98: 529–534.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level of ≤ 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–2246.
   PubMed Web of Science ®Google Scholar
• The Early Detection Research Network: Investing in Translational Research on Biomarkers of Early Cancer and Cancer Risk, Fourth Report; NIH Publication No. 07-6135, January 2008 http://edrn.nci.nih.gov/docs.
   Google Scholar
• Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.
   PubMed Web of Science ®Google Scholar
• Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007; 7: 3.
   PubMedGoogle Scholar
• Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase——an ‘obscure’ metabolic enzyme takes centre stage. FEBS J 2008; 275: 1089–1102.
   PubMed Web of Science ®Google Scholar
• Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419–1423.
   PubMed Web of Science ®Google Scholar
• Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008;14:7790–7797.
   PubMedGoogle Scholar
• Huggins C, Stevens Jr RE, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223.
   Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009; 55: 62–75.
   PubMed Web of Science ®Google Scholar
• Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000; 6: 220–233.
   PubMed Web of Science ®Google Scholar
• Hernandex J, Thompson IM. Diagnosis and treatment of prostate cancer. Med Clin North Am 2004; 88: 267–279.
   PubMedGoogle Scholar
• Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781–789.
   PubMed Web of Science ®Google Scholar
• Barry, M.J Screening for Prostate Cancer among Men 75 Years of Age or Older. N Engl J Med 2008; 359: 2515–2516.
   PubMedGoogle Scholar
• Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol 2009;4: 235–252.
   PubMed Web of Science ®Google Scholar
• Lee J, Soper SA, Murray KK. Microfluidic chips for mass spectrometry-based proteomics. J Mass Spectrom 2009;44:579–593.
   PubMed Web of Science ®Google Scholar
• Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, Chan AS, Chan AT. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009;6:123–134.
   PubMed Web of Science ®Google Scholar
• Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 2008;3:1796–1808.
   PubMed Web of Science ®Google Scholar
• Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3d, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol 2007;383:321–336.
   PubMedGoogle Scholar
• Machida K, Thompson CM, Dierck K, Jablonowski K, Kärkkäinen S, Liu B, Zhang H, Nash PD, Newman DK, Nollau P, Pawson T, Renkema GH, Saksela K, Schiller MR, Shin DG., Mayer BJ. High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell 2007;26:899–915.
   PubMedGoogle Scholar
• Kim YJ, Feild B, Fitzhugh W, Heidbrink JL, Duff JW, Heil J, Ruben SM, He T. Reference map for liquid chromatography-mass spectrometry-based quantitative proteomics. Anal Biochem 2009;393:155–162.
   PubMed Web of Science ®Google Scholar
• Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics 2009;72:740–749.
   PubMed Web of Science ®Google Scholar
• Simpson KL, Whetton AD, Dive C. Quantitative mass spectrometry-based techniques for clinical use: biomarker identification and quantification. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1240–1249.
   PubMed Web of Science ®Google Scholar
• O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250: 4007–4021
   PubMed Web of Science ®Google Scholar
• Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, and Maeda T. Proteome analysis of prostate cancer. Prostate Cancer and Prostatic Dis 2005; 8: 14–21.
   PubMed Web of Science ®Google Scholar
• Van den Bemd GJ, Krijgsveld J, Luider TM, van Rijswijk AL, Demmers JA, Jenster G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 2006;5:1830–1839.
   PubMed Web of Science ®Google Scholar
• Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009;15:4292–4298.
   PubMed Web of Science ®Google Scholar
• Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010;13:12–9.
   PubMed Web of Science ®Google Scholar
• Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009;72:907–917.
   PubMed Web of Science ®Google Scholar
• Fung KY, Glode LM, Green S, Duncan MW. A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate 2004; 61: 171–181.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006; 6: 961–967.
   PubMed Web of Science ®Google Scholar
• Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. ProteinChip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999; 2: 264–276.
   PubMedGoogle Scholar
• Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576–1578.
   PubMedGoogle Scholar
• Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609–3614.
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44–52.
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53–60.
   PubMed Web of Science ®Google Scholar
• Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer. I: assessment of platform reproducibility. Clin Chem 2005; 51: 102–112.
   PubMed Web of Science ®Google Scholar
• Belluco C, Petricoin E, Peschle C, Liu C, Lowenthal M, Johann D, Lasebikan L, Ross-Rucker S, Lise M, Di Maggio C, Mammano E, Facchiano F, Nitti D, Garaci E, Mills G, Liotta L, Whiteley G. Serum proteomic mass spectrometry a highly sensitive and specific discriminatory pattern for Stage I breast cancer. Ann Surg Oncol 2007; 14 2470–2476.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Petricoin EF. Putting the “bio” back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008; 54: 3–5.
   PubMed Web of Science ®Google Scholar
• Wright ME, Han DK, Aebersold R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 2005; 4: 545–554.
   PubMed Web of Science ®Google Scholar
• Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW. 2DDIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009;8:942–957.
   PubMedGoogle Scholar
• Vestergaard M, Tamiya E. A rapid sample pretreatment protocol: improved sensitivity in the detection of a low-abundant serum biomarker for prostate cancer. Anal Sci 2007;23:1443–1446.
   PubMedGoogle Scholar
• Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Kunle Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics 2009;3:853–861.
   PubMedGoogle Scholar
• Dekker LJ, Bosman J, Burgers PC, van Rijswijk A, Freije R, Luider T, Bischoff RJ. Depletion of high-abundance proteins from serum by immunoaffinity chromatography: a MALDI-FT-MS study. Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 65–69.
   PubMedGoogle Scholar
• Geho DH, Luchini,A Garaci E, Belluco C, Petricoin EF, Liotta LA. Nanotechnology in clinical proteomics. Nanomedicine 2007; 2: 1–5.
   PubMedGoogle Scholar
• Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-Microglobulin is an androgen regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 2007; 13: 1979–1986.
   PubMed Web of Science ®Google Scholar
• Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009; 72: 907–917.
   PubMed Web of Science ®Google Scholar
• Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008; 7: 3329–3338.
   PubMed Web of Science ®Google Scholar
• Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388–1394.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008; 7: 600–611.
   PubMed Web of Science ®Google Scholar
• Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 2005; 5: 3183–3192.
   PubMedGoogle Scholar
• Quantitative assays for tryptic peptides belonging from 53 high and medium abundance serum proteins have been designed. Mol Cell Proteomics 2006; 5: 573–588.
   PubMed Web of Science ®Google Scholar
• Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, Choquet-Kastylevsky G. Lemoine. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. J Mol Cell Proteomics 2009; 8: 1006–1015.
   PubMed Web of Science ®Google Scholar
• Sparbier K, Wenzel T, Dihazi H, Blaschke S, Müller GA, Deelder A, Flad T, Kostrzewa M. Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrometry. Proteomics 2009; 9: 1442–1450.
   PubMed Web of Science ®Google Scholar
• Geho DH, Jones CD, Petricoin EF, Liotta LA. Nanoparticles potential biomarkers harvesters. Curr Opin Chem Biol 2006;10:56–61.
   PubMed Web of Science ®Google Scholar
• Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;54:3–12.
   PubMed Web of Science ®Google Scholar
• Cavalieri F, Chiessi E, Villa R, Vigano L, Zaffaroni N, Telling MF, Paradossi G. Novel PVA-based hydrogel microparticles for doxorubicin delivery. Biomacromolecules 2008; 9: 1967–1973.
   PubMed Web of Science ®Google Scholar
• Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, Jones CD, Espina V, Patanarut A, Zhou W, Ross MM, Tessitore A, Petricoin EF 3d, Liotta LA. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 2008; 8: 350–361.
   PubMed Web of Science ®Google Scholar
• Longo C, Patanarut A, George T, Bishop B, Zhou W, Fredolini C, Ross MM, Espina V, Pellacani G, Petricoin EF 3d, Liotta LA, Luchini A. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 2009; 4: e4763.
   PubMed Web of Science ®Google Scholar
• Fredolini C, Meani F, Reeder KA, Rucker S, Patanarut A, Botterell PJ, Bishop B, Longo C, Espina V, Petricoin EF, III, Liotta LA, Luchini A. Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by cibacron blue F3G-A loaded hydrogel particles. Nano Research 2008; 1: 502–518.
   PubMed Web of Science ®Google Scholar
• Sutkeviciute I, Sereikaite J, Bumelis VA. Analysis of cibacron blue F3G-A interaction with therapeutic proteins by MALDI-TOF mass spectrometry. Biomed Chromatogr 2008; 22: 1001–1007.
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232–240.
   PubMedGoogle Scholar
• Niehans P: Prostata-Krebs wie Paraprostata-Hypertrophie sind Folgen hormonaler Störun-gen, die wir je früher je besser beeinflussen können.. Verlag Hans Huber, Bern, 1940.
   Google Scholar
• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981–991.
   PubMed Web of Science ®Google Scholar
• Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, Norstedt G, Bergman T, Pousette A. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate 2006; 66: 1235–1244.
   PubMedGoogle Scholar
• Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099–7105.
   PubMed Web of Science ®Google Scholar
• Cappello F, Rappa F, David S, Anzalone R, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10, and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res 2003; 3: 1325–1331.
   Google Scholar
• Alaiya A, Roblick U, Egevad L, Carlsson A, Franzén B, Volz D, Huwendiek S, Linder S, Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000; 21:1–9.
   PubMed Web of Science ®Google Scholar
• Rowland JG, Robson JL, Simon WJ, Leung HY, Slabas AR. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 2007; 7: 47–63.
   PubMedGoogle Scholar
• Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996; 274: 998–1001.
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Liotta LA, Petricoin EF 3d. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 2001; 57: 160–163.
   PubMedGoogle Scholar
• Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981–1989.
   PubMed Web of Science ®Google Scholar
• Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003;3 2142–2146.
   PubMed Web of Science ®Google Scholar
• Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle JD. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. Proteome Res 2009; 8: 3044–3054.
   PubMed Web of Science ®Google Scholar
• Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3d, Liotta LA, Abati A. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007;111:173–184.
   PubMed Web of Science ®Google Scholar
• Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, Brand RE, Haab BB. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007;4:437–444.
   PubMed Web of Science ®Google Scholar
• Haab BB. Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics 2010;7:9–11.
   PubMed Web of Science ®Google Scholar
• Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and protein susing MALDI-TOF MS. Anal Chem 1997;69:4751–4760.
   PubMed Web of Science ®Google Scholar
• Goodwin RJ, Pennington SR, Pitt AR. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics 2008;8:3785–3800.
   PubMed Web of Science ®Google Scholar
• Shimma S, Sugiura Y, Hayasaka T, Hoshikawa Y, Noda T, Setou M. MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. J Chromatogr B Analyt Technol Biomed Life Sci 2007;855:98–103.
   PubMed Web of Science ®Google Scholar
• Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010;9:1854–1863.
   PubMed Web of Science ®Google Scholar
• Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 2007;6:4127–4134.
   PubMed Web of Science ®Google Scholar
• Chaurand P, Rahman MA, Hunt T, Mobley JA, Gu G, Latham JC, Caprioli RM, Kasper S. Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol Cell Proteomics 2008;7:411–423.
   PubMed Web of Science ®Google Scholar
• Schwamborn K, Krieg RC, Reska M, Jakse G, Knuechel R, Wellmann A. Identifying prostate carcinoma by MALDI-imaging. Int J Mol Med 2007;20:155–159.
   PubMed Web of Science ®Google Scholar
• Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, Clements MA, Drake RR, Semmes OJ. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 2009;15:5541–551.
   PubMed Web of Science ®Google Scholar
• Thiery G, Shchepinov MS, Southern EM, Audebourg A, Audard V, Terris B, Gut IG. Multiplex target protein imaging in tissue sections by mass spectrometry-TAMSIM. Rapid Commun Mass Spectrom 2007;21:823–829.
   PubMed Web of Science ®Google Scholar
• Baker MJ, Brown MD, Gazi E, Clarke NW, Vickerman JC, Lockyer NP. Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. Analyst 2008;133:175–179.
   PubMedGoogle Scholar
• Lechene C, Hillion F, McMahon G, Benson D, Kleinfeld AM, Kampf JP, Distel D, Luyten Y, Bonventre J, Hentschel D, Park KM, Ito S, Schwartz M, Benichou G, Slodzian G. High-resolution quantitative imaging of mammalian and bacterial cells using stable isotope mass spectrometry. J Biol 2006; 5:20.
   PubMedGoogle Scholar